J Biol Chem, Vol. 275, Issue 12, 8991-9000, March 24, 2000
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor
Suppressor Protein Occurs Independently of Its Assembly with
Cullin-2*
Isabelle
Groulx,
Marie-Eve
Bonicalzi, and
Stephen
Lee
From the Department of Cellular and Molecular Medicine, Faculty of
Medicine, University of Ottawa, Ottawa,
Ontario K1H 8M5, Canada
 |
ABSTRACT |
Inactivating mutations of the von Hippel-Lindau
(VHL) tumor suppressor gene cause the VHL cancer syndrome and sporadic
renal clear cell carcinoma. VHL engages in a nucleocytoplasmic shuttle, which is required for its function. Here, we pursue our investigation to identify mechanisms by which VHL-green fluorescent protein (VHL-GFP)
is exported from the nucleus. We show that nuclear export of VHL-GFP in
living cells requires ongoing RNA polymerase II activity, and is
mediated by mechanisms that are temperature-sensitive and
energy-dependent. In vitro nuclear export of
VHL-GFP is inhibited by nuclear pore-specific lectins, requires ATP
hydrolysis and polyadenylated mRNAs, and occurs with kinetics that
are similar to those of proteins containing a nuclear export signal.
Biochemical fractionation has revealed that nuclear export of VHL-GFP
occurs by way of a Ran-dependent pathway. Size exclusion
column chromatography and deletion mutant analysis suggest that VHL-GFP
does not require assembly with one of its associated proteins,
cullin-2, to engage in nuclear export. These results demonstrate that
nuclear export of VHL-GFP is Ran-mediated and ATP
hydrolysis-dependent. They also suggest that sequences
outside the elongin C binding box may function as a nuclear export
domain, potentially providing a novel role for this region of VHL
frequently mutated in renal cell carcinoma.
 |
INTRODUCTION |
The VHL1 gene was
identified in 1993 as the tumor suppressor gene whose germ line
mutations are associated with the inherited von Hippel-Lindau cancer
syndrome (1-3). VHL patients develop a wide variety of tumors
including retinal angioma, central nervous system hemangioblastoma,
pheochromocytoma, and renal clear cell carcinoma (RCC). Biallelic VHL
gene defects are also found in the sporadic form of these tumors,
including RCC, the most common type of kidney cancer in human (4, 5).
It is hypothesized that VHL exerts gatekeeper function in renal
proximal tubule cells, which are thought to give rise to RCC (6-8).
VHL-negative RCC form tumors in nude mice that are suppressed by the
reintroduction of VHL, consistent with its gatekeeper function (9). In
addition, the reintroduction of VHL in VHL-negative RCC restored their
ability to regulate levels of hypoxia-inducible mRNAs (10-13), to
form an extracellular matrix (14), to induce differentiation of RCC grown as multicellular tumor spheroids (15), and to exit the cell cycle
in low serum (8).
The mechanism by which VHL is able to function as a gatekeeper tumor
suppressor still remains unknown. The VHL mRNA produces two
proteins from alternative in-frame methionines of 213 and 160 amino
acids that do not share sequence similarity with other proteins, thus
giving no clues as to their functions (both forms will be referred to
as "VHL") (16-18). VHL assembles into a core heterotetrameric
complex with three other associated proteins: elongin B, elongin C, and
cullin-2 (VBC/Cul-2) (12, 19-21). Structural similarity between
elongin C and cullin-2 with two components of a yeast E3-ubiquitin
ligase complex, SKP1 and CDC53, respectively, has led to the suggestion
that VBC/Cul-2 may play a role in protein ubiquitination (20-22). This
model is further supported by the recent discovery that VBC/Cul-2
assembles with Rbx1 (23), and acts as an E3-ubiquitin ligase in
vitro (24). One potential target of VBC/Cul-2-mediated degradation
is the hypoxia-inducible factor-
subunit, a protein involved in the
regulation of several hypoxia-inducible mRNAs (25). VBC/Cul-2 might
regulate specific mRNAs including vascular endothelial growth
factor, glucose transporter-1 (Glut-1), and transforming growth
factor-
through its ability to modulate levels of hypoxia-inducible
factor-
subunit (10-13, 25, 26). Disruption of VBC/Cul-2 by
tumor-derived mutations results in the abnormal stabilization, and
accumulation, of vascular endothelial growth factor, Glut-1, and
transforming growth factor-
mRNAs, suggesting a role for the
complex in the processing of these transcripts (12).
Another intriguing characteristic of VHL is that it is able to localize
to the nucleus and the cytoplasm, and shuttle between these two
compartments (9, 27-32). VHL shuttling is sensitive to ongoing RNA
polymerase II activity, but is not affected by treatment with
leptomycin B, a drug that affects CRM1-mediated nuclear export of
protein containing a classical, leucine-rich nuclear export signal
(NES; Refs. 33 and 34). Likewise, VHL was unable to function as a
negative regulator of Glut-1 levels when it was fused to a classical
NES and induced to shuttle in a leptomycin B-sensitive, but
transcription-insensitive, manner (29). These observations suggested
that VHL might export from the nucleus through a yet undescribed
pathway. Therefore, we decided to pursue our studies on VHL subcellular
trafficking by investigating the mechanisms involved in its regulated
nuclear export. We show that VHL nuclear export occurs through a
Ran-mediated and ATP hydrolysis-dependent pathway. VHL exports
from the nucleus bound to complexes containing cullin-2, but appears to
be able to mediate its own nuclear export and that of an inert green
fluorescent protein (GFP) reporter. These results provide evidence that
VHL contains a nuclear export domain, which might play a role in
nuclear export of the VBC/Cul-2 complex.
 |
MATERIALS AND METHODS |
Cell Culture and Transfections--
The 786-0 (VHL-negative) and
HeLa cells were obtained from the American Type Culture Collection
(Rockville, MD). The VHL-GFP cell line corresponds to a 786-0 stably
transfected with the VHL-GFP fusion protein as described elsewhere
(29). All cells were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% (v/v) fetal calf serum in a 37 °C,
humidified, 5% CO2-containing-atmosphere incubator.
Transient transfections of HeLa cells were performed overnight using a
standard calcium phosphate method.
Expression Vectors and Constructs--
The human VHL cDNA,
which codes for a 213-amino acid VHL protein, was subcloned into
pcDNA3.1(
) (Invitrogen) vector. A Flag epitope tag (DYKDDDDK) was
added to the N terminus of the VHL cDNA open reading frame. A
cDNA coding for an enhanced fluorescence version of the GFP
(Fred25; Ref. 35) was subcloned at the C terminus VHL to produce the
VHL-GFP fusion protein. A deletion mutant of the last 56 amino acids
was also fused to GFP to produce the
C157-GFP fusion protein. The
VHL moiety was also replaced by a full-length cullin-2 cDNA (21) to
produce cullin-2-GFP. The open reading frame of chicken pyruvate kinase
(PK) fused to GFP (PK-GFP), and two GFP in tandem (GFP-GFP), were
cloned into pcDNA3.1(
). The NLS fusion proteins were produced by
fusing the strong NLS of simian virus 40 (SV40; Ref. 36) large T
antigen (PKKKRKKV; NLS) to the C terminus of GFP. All constructs were verified by DNA sequencing.
In Vitro Nuclear Export Assay--
The nuclear export assay was
essentially as described (37-40). Cells were plated on a 35-mm dish
with a hole at the bottom replaced by a glass coverslip. Cells were
grown to confluence, washed with PBS and incubated 1 min in the
presence of transport buffer containing 20 mM HEPES pH 7.3, 110 mM KOAc, 5 mM NaOAc, 2 mM
Mg(OAc)2, 1 mM EGTA, and 2 mM DTT.
The cells were permeabilized at 4 °C for 5 min in the presence of
transport buffer containing 50 µg/ml digitonin and a protease
inhibitor mixture including 1 mM phenylmethylsulfonyl
fluoride, 0.5 µg/ml leupeptin, and 1 µg/ml aprotinin. Cells were
washed several times with transport buffer and protease inhibitor
mixture for 15 min at 4 °C. Cells were incubated for the indicated
time, generally 30-45 min, at 20 °C in the presence of the standard
reaction mixture that included transport buffer, HeLa cytosol, 2 mM ATP, 2 mM GTP, and an ATP-regenerating system (5 mM creatine phosphate and 20 units/ml creatine
phosphokinase). Where indicated, ATP and GTP were omitted or replaced
with AMP-PNP and GMP-PNP at 2 mM, respectively. Wheat germ
agglutinin (WGA) was added, as indicated, at a concentration of 200 µg/ml. The overall volume of the reaction mixture was 0.5-1 ml. For
the preincubation experiments, permeabilized cells were incubated 15 min at 4 °C in the presence of transport buffer, followed by an
incubation of 30 min at 20 °C in the presence of transport buffer
and 2 mM ATP, 2 mM GTP, and an ATP-regenerating
system before the addition of the standard reaction mixture. Reactions
were stopped by washing the cells several times with ice-cold transport
buffer. For biochemical analysis of export, cells were trypsinized,
washed in PBS, permeabilized in the presence of transport buffer with
50 µg/ml digitonin for 5 min at 4 °C supplemented with the
protease inhibitor mixture, and subsequently washed several times with
cold transport buffer for 15 min at 4 °C. Nuclei were aliquoted in
1.5-ml tubes and treated as described above. Export was terminated by
centrifugation at 300 × g at 4 °C for 2 min to
separate nuclei from the supernatant. Nuclei were lysed in the presence
of 1% Triton X-100, 20 mM Tris-HCl (pH 8.0), 137 mM NaCl with protease mixture for 30 min at 4 °C, or
with 4% SDS in PBS. 4× SDS-sample buffer was added to aliquots of
nuclear lysates and supernatant, which were separated on SDS-PAGE, and
blotted onto nitrocellulose using standard methods. Blots were blocked
with 5% milk powder in PBS containing 0.1% Tween 20, incubated with
the indicated antibodies at a concentration of 1 µg/ml for 16 h
at 4 °C, washed, and incubated with a horseradish peroxidase-coupled
donkey anti-mouse or anti-rabbit antibody (1:5000) for 60 min at room
temperature. The enhanced chemiluminescence system was used to detect
signal (Amersham Pharmacia Biotech). Blots were also incubated with
other antibodies; an anti-p27 antibody at 1:1000 (Transduction
Laboratories) and an anti-cyclin B antibody at 1:1000 (Santa Cruz) and
a rabbit anti-cullin-2 antibody at 1:5000.
Fluorescence Analysis and Image Processing--
Nuclear GFP
fluorescence images were captured using a Zeiss Axiovert S100TV
microscope with a C-Apochromat 40× water immersion objective, equipped
with an Empix digital charge-coupled device (CCD) camera using Northern
Eclipse software. Images were manipulated with Northern Eclipse, NIH
Image, and Adobe Photoshop software as described elsewhere (29).
Briefly, relative nuclear signals were measured as followed. Images
were obtained with identical integration time, usually 0.5-3 s at a 2 by 2 binning with an electronic gain of 2. Images were always taken
under nonsaturating conditions. Three random images containing between
30 and 45 independent nuclei, which could be observed with Hoechst
staining, were captured within 30-45 s. GFP images were always taken
before the Hoechst images to minimize any possible bleaching effect.
Hoechst positive regions were used to identify and measure GFP signal
in the different nuclei. Reactions were standardized using an arbitrary
value of 100%, which corresponded to signal obtained immediately after the 15-min washing step at 4 °C. Approximately 90% of nuclei were positive for GFP signal over background, whereas 10% of nuclei showed
either weak or no fluorescence signal. Values were average from three
independent experiments, always using a new 100% standard in each
experiment. For the time lapse imaging, images were captured as
described above but with one main difference to eliminate bleaching that occurs during the repeated exposure to 488 nm light. Bleaching was
measured at ~ 2% per picture and taken into account for quantification.
Purification of the Major HeLa Cytosolic Activity for VHL Nuclear
Export--
One ml of HeLa cytosol was loaded on a Superdex S-200
column equilibrated with 10 mM HEPES (pH 7.3) and 10 mM NaCl using a flow rate of 0.6 ml/min and collecting 25 fractions of 0.5 ml. Half of each other fractions were added to ATP/GTP
and an ATP regeneration system to test for nuclear export of VHL-GFP.
Aliquots of 50 µl of some of the fractions were also separated on
SDS-PAGE, blotted on nitrocellulose, and incubated in the presence of
anti-Ran antibody (Transduction Laboratories). Recombinant Ran and
RanG19V were a kind gift from Dr. Mary Dasso (National Institutes of
Health, Bethesda, MD) and added to the export reaction at a
concentration of 100 µg/ml. For experiments shown in Fig. 5, Ran was
produced as described (41). Briefly, bacteria expressing Ran were
pelleted and resuspended in 1/20 volume of transport buffer and a
mixture of protease inhibitor. The bacterial suspension was lysed by
sonication, and the lysate was centrifuged at maximum speed in an
Eppendorf microcentrifuge for 30 min. The supernatant was further
centrifuged at 80,000 × g for 30 min at 4 °C. The
supernatant was either used directly or diluted 1:1 in transport buffer
immediately before using in transport reaction. Higher dilution of the
lysate resulted in a marked loss of nuclear export of VHL-GFP.
Bacterial lysate alone did not support VHL-GFP nuclear export in
vitro (see Fig. 3A).
 |
RESULTS |
Nuclear Export of VHL-GFP in Living Cells--
We have previously
reported that nucleocytoplasmic shuttling of VHL-GFP is insensitive to
leptomycin B treatment raising the possibility that nuclear export of
VHL-GFP occurs through a CRM-1-independent pathway (29). However, it
was unclear if nuclear export of VHL-GFP was the outcome of simple
passive diffusion through the nuclear pore complex or if it required
energy-dependent mechanisms. The dependence on NTP
hydrolysis would suggest that VHL-GFP might utilize a specific,
transporter-mediated nuclear export pathway (42). Two independent
strategies were developed to test if energy is required for nuclear
export of VHL-GFP in living cells. First, transiently transfected HeLa
cells were incubated in the presence of the RNA polymerase II inhibitor
DRB, which induced VHL-GFP to change its steady state distribution from
cytoplasmic to mainly nuclear (Fig.
1A, a and
b; see also Ref. 29). Reactivation of RNA polymerase
II-mediated transcription, by washing away DRB, caused VHL-GFP to
reestablish a predominately cytoplasmic distribution (Fig.
1A, c) without any changes in level of
fluorescence (data not shown and Ref. 29). As these experiments are
performed in the presence of cycloheximide, the return of VHL-GFP to
the cytoplasm can only be explained by the ability of existing
molecules to export from the nucleus. The redistribution of VHL-GFP to
the cytoplasm is inhibited when cells are incubated at 4 °C or in the presence of metabolic poisons (Fig. 1A, d and
e), suggesting that nuclear export of VHL-GFP is an
energy-dependent process. The ability of the VHL-GFP fusion
protein to export from the nucleus is mediated by the VHL moiety, since
replacing it by another GFP (GFP-GFP) resulted in a fusion protein
whose localization was unaffected by DRB or metabolic poisons (data not
shown; Ref. 35). The second approach consisted of a strategy by which
VHL-GFP was forced to localize exclusively to the nucleus by way of its
fusion to the strong, temperature-sensitive, and
energy-dependent SV40 nuclear import signal (VHL-GFP-NLS;
Fig. 1, B and C (a); Ref. 36). We
reasoned that VHL-GFP-NLS would accumulate in the cytoplasm upon
incubation of cells at 4 °C, or in the presence of metabolic poisons, since the fusion protein would fail to reimport in these conditions. VHL-GFP-NLS localized exclusively in the nucleus even in
conditions where NLS activity was inhibited (Fig. 1C,
b and c), suggesting that it is unable to
passively diffuse out of the nucleus. The VHL moiety was replaced by
another GFP to produce the GFP-GFP-NLS fusion protein whose mass and
nuclear localization were similar to that of VHL-GFP-NLS (60 kDa; Fig.
1, B and C (d)). In contrast to
VHL-GFP-NLS, GFP-GFP-NLS was readily detectable in the cytoplasm upon
incubation at 4 °C, or with metabolic poisons, indicating that this
fusion protein is able to egress from the nucleus by passive diffusion
(Fig. 1C, e and f; Ref. 43). Such as
VHL-GFP-NLS, a large fusion protein consisting of pyruvate kinase fused
to GFP and NLS (PK-GFP-NLS) remained restricted to the nucleus,
regardless of the different treatments (Fig. 1, B and
C (g-i)). Put together, these results suggest
that the VHL moiety is able to confer nuclear export activity to a
reporter GFP in living cells, which requires ongoing RNA polymerase II activity and energy.

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 1.
Nuclear export of VHL-GFP in living
cells. A, effect of RNA polymerase II activity on
VHL-GFP localization in living cells. Transiently transfected HeLa
cells expressing VHL-GFP (a) were treated with 25 µg/ml
DRB for 2 h at 37 °C (b). Cells were washed and
incubated for 2 h in the presence of cycloheximide (25 µg/ml) at
37 °C (c), at 4 °C (d), or at 37 °C in
the presence of 6 mM 6-deoxyglucose, 0.02% sodium azide
(e). B, schematic diagram of NLS fusion proteins.
VHL-GFP was fused at its C terminus to the SV40 large T antigen NLS
(PKKKRKV) to produce the VHL-GFP-NLS fusion protein. The VHL moiety was
replaced by another GFP (GFP-GFP-NLS) or by pyruvate kinase
(PK-GFP-NLS). The approximate molecular size (MW), evaluated
by SDS-PAGE and Western blotting with an anti-GFP antibody, is given in
kilodaltons (kDa). C, effect of temperature and energy
depletion on the localization of NLS fusion proteins. HeLa cells were
transiently transfected with the VHL-GFP-NLS (a),
GFP-GFP-NLS (d), and PK-GFP-NLS (g) constructs.
Cells were incubated for 2 h at 4 °C (b,
e, h) or at 37 °C in the presence of
6-deoxyglucose/sodium azide (c, f,
i).
|
|
An in Vitro System to Study Nuclear Export of VHL-GFP--
The
results obtained in living cells suggested that VHL might utilize an
energy-dependent mechanism to export from the nucleus. To
identify cellular factors involved in this putative process, we used a
VHL-GFP in vitro nuclear export assay based on the
digitonin-permeabilization system (37-40, 44). This system has been
utilized to characterize proteins that contain specific sequences
directing their nuclear import or export (38, 44-49). VHL-negative RCC
786-0 cells that stably express reintroduced VHL-GFP to very low
levels, similar to those of endogenous VHL (29), were treated with
digitonin causing the complete loss of cytoplasmic signal while
retaining nuclear VHL-GFP (Fig.
2A). The specific nuclear
VHL-GFP signal should not be confused with the 786-0 autofluorescence,
distinguished as perinuclear dots. To test if VHL-GFP is able to export
from nuclei in vitro, permeabilized cells were incubated in
standard nuclear export conditions that included transport buffer
supplemented with cytosolic extract from HeLa cells, ATP, and GTP, as
well as an ATP regeneration system (Fig. 2B). Efficient
nuclear export was observed after incubation for 30 min at 20 °C, as
evidenced by an important loss of nuclear signal (Fig. 2B,
a-d; compare a to c and Fig.
2C for quantitation). VHL-GFP failed to export from nuclei
when permeabilized cells were incubated in standard conditions for 30 min at 4 °C (Fig. 2, B (e-h) and
C) or at 20 °C with WGA, an inhibitor of signal-mediated
nuclear transport (Fig. 2, B (i-l) and
C). Both DRB and cordycepin, an inhibitor of polyadenylation
of mRNA, partially inhibited the ability of VHL-GFP to export from
nuclei (Fig. 2D), in a manner reminiscent of their effect in
living cells. Nuclear export of VHL-GFP was also monitored using a
biochemical assay. Loss of nuclear signal was only observed when cells
were incubated in standard conditions for 30 min at 20 °C but not at
4 °C, or with WGA, confirming data obtained with the imaging
procedures (Fig. 2E). Lysates were blotted for the nuclear
cyclin-dependent kinase inhibitor p27 and cyclin B, a
protein that contains a classical NES and whose subcellular distribution at steady state is similar to that of VHL-GFP (50, 51).
p27, detected as a doublet in 786-0 cells, and cyclin B readily
exported from nuclei upon incubation at 20 °C, but not at 4 °C or
with WGA, indicating that the in vitro assay can sustain nuclear export of known exportable substrates. Fig.
3F shows that VHL-GFP
accumulated in the supernatant, indicating that the loss of nuclear
signal is not due to degradation of the fusion protein. The
t1/2 of VHL-GFP nuclear export was determined to
be 6-7 min by time lapse imaging procedures (Fig. 2, G and
H, for quantitation). These results demonstrate that nuclear
export of VHL-GFP is an efficient, temperature-sensitive, and
signal-mediated phenomenon that occurs in a manner similar to that of
substrates that contain characterized nuclear export activities.

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 2.
In vitro reconstitution of VHL-GFP
nuclear export. A, digitonin treatment of 786-0 cells
expressing VHL-GFP resulted in the exclusive loss of cytoplasmic
signal. Cells were not treated ( digitonin) or treated with
digitonin (50 µg/ml) in transport buffer (+digitonin). The
corresponding Hoechst signal is shown on the right side.
Arrows in b and d point at different
nuclei after digitonin treatment to show nuclear VHL-GFP. Notice that
the perinuclear dots are due to 786-0 autofluorescence and should not
be confused with specific VHL-GFP signal. B, nuclear export
of VHL-GFP in vitro. VHL-GFP-expressing 786-0 cells were
permeabilized with digitonin, washed for 15 min at 4 °C, and
incubated in the presence of transport buffer supplemented with HeLa
cytosolic extract (2 mg/ml), ATP/GTP (2 mM each) and an ATP
regeneration system, for 0 min (a, e,
i) or 30 min at 20 °C (c), at 4 °C
(g), or at 20 °C but with 200 µg/ml WGA (k).
Hoechst staining is presented (b, d,
f, h, j, l). C,
quantitative analysis of nuclear export of VHL-GFP in vitro.
CCD camera-captured images were quantified with NIH image and Northern
Eclipse softwares. At least 100 nuclei were analyzed in three
independent experiments. Average values ± standard errors are
presented in relation to signals measured immediately after the 15-min
washing step (prior to export; 0'). D, effect of
DRB and cordycepin on in vitro nuclear export of VHL-GFP.
Cells were treated with 25 µg/ml DRB or 50 µg/ml cordycepin for
2 h at 37 °C, permeabilized, and incubated in the presence of
complete nuclear export reaction mixture supplemented with DRB or
cordycepin for 30 min at 20 °C. Quantitative analysis is shown.
E, biochemical analysis of VHL-GFP nuclear export. 786-0 cells expressing VHL-GFP were trypsinized, washed in PBS, and
permeabilized. Nuclei were incubated in the presence of complete
nuclear export reaction mixture for 0 and 30 min at 20 °C, at
4 °C, or at 20 °C with WGA (200 µg/ml). Nuclei were collected
by centrifugation, washed twice with ice-cold transport buffer, and
lysed with 4% SDS in PBS. Blots were incubated with an anti-FLAG M2
antibody (VHL-GFP), an anti-p27 antibody
(p27), and an anti-cyclin B antibody (Cyclin
B). F, VHL-GFP accumulates in the supernatant
fraction during in vitro nuclear export. After incubation of
nuclei for 0 and 30 min at 20 °C with complete nuclear export
reaction mixture, the nuclei were collected by centrifugation and equal
aliquots of supernatant fractions (0 and 30 min) were separated on
SDS-PAGE, transferred to membrane, and blotted with an anti-FLAG M2
antibody. G, the t1/2 of VHL-GFP
nuclear export in vitro is comparable to that of other
exportable substrates. Time lapse imaging of digitonin-permeabilized
cells incubated at 20 °C in the presence of a complete export
reaction mixture in the absence ( WGA) or presence of 200 µg/ml WGA (+WGA) for the indicated time. H,
quantitative analysis of the nuclear export rate of VHL-GFP in the
presence or absence of WGA. Average and standard error of three
independent experiments are shown.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
Identification of the small GTPase Ran as the
major activity in HeLa cytosolic extract that stimulates in
vitro nuclear export of VHL-GFP. A,
cytosolic factor requirement for VHL-GFP nuclear export in
vitro. Digitonin permeabilized 786-0 cells expressing VHL-GFP were
incubated for 30 min at 20 °C in the presence of transport buffer
supplemented with 2 mM each ATP/GTP, an ATP regeneration
system and either with 2 mg/ml (+lysate) or without
( lysate) HeLa cytosolic extract, or with 2 mg/ml each of
extract from 786-0 RCC cells (+kidney lysate),
Cos-7 cells, mouse NIH 3T3 cells, and E. coli cells.
Quantitative analysis is shown. B, profile of VHL-GFP
nuclear export activity of fractions collected from a Superdex-200
column. Twenty-five fractions of ~0.5 ml were collected at a flow
rate of 0.6 ml/min. Reaction mixtures contained transport buffer, 2 mM each ATP/GTP, an ATP regeneration system, and 20% of
each other fractions. Molecular sizes (MW) for fractions
represent values obtained from Amersham Pharmacia Biotech and are based
on the flow rate. VHL-GFP nuclear export was measured
semiquantitatively on 14 of the 25 fractions in comparison with 4 °C
transport buffer control and scored as: , no or only slight export;
+/ , detectable export; and ++, export levels similar to those
obtained with HeLa extract. An aliquot of 50 µl of each fraction was
separated on SDS-PAGE, transferred to nitrocellulose, and incubated
with an anti-Ran antibody. Ran migrates at about 25 kDa and eluted from
the Superdex-200 column in the 10-60-kDa range, although longer
exposure revealed the presence of Ran in fractions 5-12. C,
effect of purified recombinant Ran on VHL-GFP in vitro
nuclear export. VHL-GFP-expressing 786-0 cells were permeabilized with
digitonin and incubated for 30 min with transport buffer, 2 mM each ATP/GTP, an ATP regeneration system, and either
without ( Ran, a) or with 100 µg/ml Ran
(+Ran, b) at 20 °C or with Ran but at 4 °C
(+Ran, 4 °C, c). D, biochemical
analysis of Ran-dependent VHL-GFP nuclear export in
vitro. 786-0 cells expressing VHL-GFP were trypsinized, washed in
PBS, and permeabilized with digitonin. Nuclei were incubated at
20 °C with transport buffer containing 2 mM ATP/GTP, an
ATP regeneration system without ( Ran) or with
(+Ran) 100 µg/ml recombinant Ran. Reaction time was either
0 or 30 min, as indicated. Nuclei were collected by centrifugation and
separated from
the supernatant fraction. Equal aliquots of nuclear
(N) and supernatant (S) fractions were separated
on SDS-PAGE. Blots were incubated with an anti-FLAG M2 antibody, to
detect VHL-GFP. E, effect of Ran on VHL-GFP nuclear export
after 30-min preincubation of permeabilized cells with ATP/GTP.
Permeabilized cells were washed for the standard 15 min at 4 °C and
then incubated for another 30 min at 20 °C in transport buffer
containing 2 mM ATP/GTP and an ATP regeneration system.
Cells were washed twice with ice-cold transport buffer and incubated
for 30 min at 20 °C in transport buffer, 2 mM ATP/GTP,
an ATP regeneration system, and either without ( Ran,
a) or with (+Ran, b) at 100 µg/ml.
|
|
Nuclear Export of VHL-GFP Requires Ran and ATP
Hydrolysis--
Proteins differ considerably in their requirements for
soluble cytosolic factors for efficient nuclear export in
vitro. The next step consisted of testing if soluble cytosolic
factors are required for nuclear export of VHL-GFP. Complete nuclear
export of VHL-GFP required the addition of HeLa cytosolic factors
although some loss of nuclear signal could be detected in the absence
of extract (Fig. 3A). Cytosolic extracts from other
mammalian cells, including kidney cells, but not from Escherichia
coli stimulated VHL-GFP nuclear export to levels similar to those
of HeLa (Fig. 3A). To identify which major cytosolic
activity is capable of promoting VHL-GFP nuclear export, HeLa extracts
were loaded on a gel filtration column and every other fraction were
tested for activity. Fractions in the 10-60-kDa range showed greater
activity compared with higher molecular mass fractions (Fig.
3B). Ran, a small GTP-binding protein of 25 kDa, is a key
component of the nuclear/cytoplasmic transport machinery (38, 46, 52,
53) and is lost from cells upon digitonin treatment and washing at 4 °C. We found that fractions that were the most efficient in stimulating nuclear export of VHL-GFP corresponded to the ones containing higher amounts of Ran (Fig. 3B). This observation
led us to directly test the involvement of Ran in nuclear export of VHL-GFP. Fig. 3C shows that purified Ran is able to
stimulate nuclear export of VHL-GFP to levels similar to those obtained with the HeLa extract. Western blot analysis indicated that VHL-GFP efficiently exported from nuclei and accumulated in the supernatant in
the presence of Ran (Fig. 3D). No difference in total amount of VHL-GFP signals could be detected between 0 and 30 min, in either
the absence or the presence of Ran. Thus, VHL-GFP is exported from
nuclei and there is no intranuclear or cytosolic degradation of the
fusion protein in the presence of Ran and NTPs. It has been reported
that a preincubation step of permeabilized cells at 20 °C in the
presence of NTPs depleted nuclei of specific nuclear transport factors
required for nuclear export of proteins harboring a classical NES (52).
In this assay, we noticed that Ran was sufficient to mediate nuclear
export of VHL-GFP, regardless of a preincubation step with ATP (Fig.
3E). These results suggest that Ran is the major cytosolic
factor that stimulates in vitro nuclear export of VHL-GFP,
which is lost upon permeabilization.
Ran-mediated nuclear export of substrates appears not to require NTP
hydrolysis (53). However, we noticed that the presence of NTP is
required for efficient nuclear export of VHL-GFP stimulated by HeLa
cytosolic extract (Fig. 4A,
a and b; quantitation is presented in Fig.
4B). Omission of ATP essentially inhibited nuclear export (Fig. 4A, c). Loss of nuclear signal was measured
when GTP was not added to the export mixture (Fig. 4A,
d), although we generally observed that the addition of GTP
(Fig. 4A, a) or non-hydrolyzable GTP analogs
GMP-PNP (Fig. 4A, e) or GTP
S (data not shown)
was required for optimal VHL-GFP nuclear export. VHL-GFP failed to export when ATP was replaced by AMP-PNP (Fig. 4A,
f and g). Similar data were obtained when the
extract was substituted with Ran (Fig. 4C). A Ran mutant,
RanG19V, which binds GTP but is unable to support hydrolysis, was
tested in the assay. RanG19V supported VHL-GFP nuclear export to levels
similar to those of wild-type Ran as long as ATP was added to the
export reaction mixture (Fig. 4C). Therefore, an ATP
hydrolysis step is absolutely required for VHL-GFP nuclear export
whereas the presence of GTP, or non-hydrolyzable GTP analogs, is only
necessary for optimal nuclear export.

View larger version (86K):
[in this window]
[in a new window]
|
Fig. 4.
VHL-GFP nuclear export requires ATP
hydrolysis but not Ran-mediated GTP hydrolysis. A, NTP
hydrolysis requirement for VHL-GFP in vitro nuclear export
in presence of HeLa cytosolic extract. Digitonin-permeabilized 786-0 cells expressing VHL-GFP were incubated for 30 min at 20 °C in the
presence of transport buffer supplemented with HeLa cytosolic extract
(2 mg/ml), an ATP regeneration system and 2 mM each
ATP/GTP(a), no ATP/GTP (b), no ATP and 2 mM GTP (c), 2 mM ATP and no GTP
(d), 2 mM ATP and 2 mM GMP-PNP
(e), 2 mM AMP-PNP and 2 mM GTP
(f), and 2 mM each AMP-PNP/GMP-PNP
(g). A few representative nuclei are encircled.
B, quantitative analysis of the mean of three independent
experiments with standard errors is presented. C, NTP
hydrolysis requirement for VHL-GFP in vitro nuclear export
in presence of Ran. Permeabilized cells were incubated with transport
buffer, an ATP regeneration system, and with Ran (Ran), or
Ran harboring a single amino acid substitution at amino acid 19 (Gly
Val). Two mM amounts of each NTP, or nonhydrolyzable
analogs, were included in the reaction mixture, as indicated.
|
|
VHL Encodes Sequences That Direct Nuclear Export of GFP--
It
has been reported that VHL assembles into complexes that contain
cullin-2 (8, 12). Cullin-2 does not bind directly to VHL but first
requires assembly with elongin C, which protein then assures complex
formation by binding to the elongin C box on VHL (12). The in
vitro biochemical characterization of VHL-GFP nuclear export
enabled the analysis of the nucleocytoplasmic distribution of
VHL-GFP/cullin-2 complexes. Western blot analysis revealed that about
90% of VHL-GFP, as well as endogenous cullin-2, can be detected in the
cytosolic fraction, whereas 10% can be found in the nuclear fraction
(Fig. 5A, upper and
middle panels) in agreement with data obtained by
digital camera (28). Immmunoprecipitation analysis, using anti-FLAG
antibodies directed against the VHL-GFP fusion protein (VHL-GFP is
fused to a N-terminal FLAG-tag) revealed that cullin-2 assembled with
VHL-GFP in the nucleus and the cytoplasm (Fig. 5A,
bottom panel).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 5.
Characterization of nuclear export of
VHL-GFP/cullin-2 complexes in vitro.
A, subcellular distribution of VHL-GFP, cullin-2, and
VHL-GFP/cullin-2 complexes. VHL-GFP stably expressing 786-0 cells were
trypsinized, washed in PBS, and treated with 50 µg/ml digitonin for 5 min at 4 °C. The nuclei were collected by centrifugation (300 × g) and separated from the cytosolic fraction. Nuclei were
washed in ice-cold transport buffer and treated with Triton X-100 for
30 min at 4 °C. Equal portions of the Triton-soluble nuclear
fraction and cytosolic fraction were run on a SDS-PAGE.
Total and 786-0 correspond to unfractionated
Triton-soluble cellular lysate obtained from 786-0 expressing VHL-GFP,
or parental 786-0 cells, respectively. Blots were incubated with an
anti-M2 antibody directed toward the N-terminal FLAG-tag of VHL-GFP
(upper panel) or with an anti-cullin-2 antibody
(middle panel). Fractions were also
immunoprecipitated with M2-beads. Beads were washed, boiled in 2× SDS
loading buffer, and loaded on SDS-PAGE. After transfer, the blots were
incubated with the anti-cullin-2 antibody (lower
panel). B, nuclear export of cullin-2 in
vitro. Digitonin-treated cells were incubated at 20 °C for the
indicated time either in the presence of transport buffer alone
(buffer) or transport buffer supplemented with Ran and an
ATP regeneration system (Ran). Nuclei were collected from
the supernatant by centrifugation and lysed in Triton, and equal
aliquots of nuclear and supernatant fractions were loaded on a 8%
SDS-PAGE. Blots were incubated in the presence of an anti-cullin-2
antibody. Reaction mixture consists of the transport buffer with Ran
and an ATP regeneration system, without permeabilized cells.
786-0 refers to permeabilized 786-0 cells. C,
analysis of in vitro nuclear export of VHL-GFP/cullin-2
complexes. Permeabilized cells were incubated for 30 min at 20 °C
either in transport buffer alone (buffer) or transport
buffer supplemented with Ran and an ATP regeneration system
(Ran/Energy). Nuclei were collected by
centrifugation and lysed in Triton, and the nuclear and supernatant
fractions were immunoprecipitated with anti-FLAG beads. Beads were
washed several times, boiled, and loaded on 8% SDS-PAGE. The top part
of the blot was incubated with an anti-cullin-2 antibody
(Cullin-2), whereas the bottom part was incubated with an
anti-FLAG antibody (VHL-GFP). Heavy chain is
detected below the specific VHL-GFP signal. The same experiments were
conducted in the presence of 10-100 µg/ml amounts of a peptide
comprising the elongin C binding box of VHL as described in Ref. 24.
D, a population of nuclear VHL-GFP does not assemble to
cullin-2 and is still able to export from nuclei in vitro.
Top panel, permeabilized cells lysate were loaded
on a Superdex-200 column and fractions were incubated in the presence
of anti-Flag beads. Beads were washed, boiled, and loaded on 8%
SDS-PAGE. After transfer, filters were incubated with anti-cullin-2
antibody (Cullin-2) or anti-Flag antibody
(VHL-GFP). Signal under VHL-GFP is from the heavy
chain of anti-Flag antibody. Bottom panels, the
panels underneath are either a longer exposure of the same autoradiograms as shown above
(fractions 5-9; Nuclear) or fractions of the supernatant
collected after the nuclear export reaction (fractions 5-9;
Supernatant). Notice the presence of VHL-GFP signal, but not
of cullin-2, in fractions 8 and 9 in both the nuclear and supernatant
conditions. Longer exposure time revealed VHL-GFP signal in fraction 10 and cullin-2 signal in fractions 5 and 8 (data not shown).
|
|
Since VHL-GFP/cullin-2 complexes were detectable in the nuclear
fraction, we used the in vitro nuclear export system to
examine if VHL-GFP exported from nuclei assembled in complexes that
contained cullin-2. Cells were permeabilized with digitonin, and the
nuclei were collected by centrifugation and washed several times to
remove the cytosolic fraction. Nuclei were resuspended in a transport buffer alone or containing an ATP regeneration system and Ran. After
the indicated time, the nuclei were collected by centrifugation and
separated from the supernatant. Western blot analysis revealed that
cullin-2 is exported from the nuclei to the supernatant in a
Ran-dependent manner (Fig. 5B). The nuclear and
supernatant fractions were immunoprecipitated with anti-FLAG beads as
described above (Fig. 5C). VHL-GFP/cullin-2 complexes were
found in the supernatant fractions when nuclear export reactions were
carried out at 20 °C and in the presence of Ran and an ATP
regeneration system, suggesting that VHL-GFP is able to export from the
nuclei assembled with cullin-2. The nuclear export reactions were also carried out in the presence of a synthetic peptide comprising the
elongin C-binding box motif of VHL. This peptide is able to prevent the
in vitro assembly of VHL with elongin-C/cullin-2 (20, 24),
but is unable to cause the disassembly of a preformed VHL-GFP/elongin C/cullin-2 complex (data not shown). We reasoned that the peptide would
prevent reassembly of VHL-GFP/elongin C/cullin-2 complexes in the
supernatant if VHL and cullin-2/elongin C proteins exported from nuclei
independently. The results obtained with the peptide were exactly the
same as the ones obtained without the peptide (Fig. 5C and
data not shown), suggesting that VHL-GFP is able to export from nuclei
assembled in complexes that contained cullin-2. We next wanted to test
if a population of nuclear VHL-GFP was able to engage in nuclear export
even though it was not assembled to cullin-2. Nuclear lysates were
loaded on a size exclusion column, and complexes were separated based
on their molecular weight. Anti-Flag immunoprecipitation analysis
revealed a population of nuclear VHL-GFP in lower molecular weight
fractions, which are lacking cullin-2 (Fig. 5D,
top panel, lanes 8 and
9). The two bottom panels
show the distribution of VHL-GFP/cullin-2 complexes before nuclear
export (Nuclear) and after completion of the export reaction
(Supernatant). In both cases, a clear VHL-GFP signal, without a strong corresponding cullin-2 signal, could be observed in
fractions 8 and 9. Long exposure time of the autoradiograms revealed
some detectable cullin-2 signal in fraction 5 and 8 and VHL-GFP signal
in fraction 10 (data not shown). These results suggest that VHL-GFP is
able to engage in nuclear export regardless of its assembly with
cullin-2.
We then investigated if VHL was able to confer
transcription-dependent nuclear export properties to
cullin-2. The subcellular localization of a cullin-2-GFP fusion protein
in transiently transfected HeLa cells was observed to be very similar
to that of VHL-GFP, but failed to redistribute to the nucleus upon
addition of DRB (Fig. 6A,
compared with Fig. 1A). It should be noted that the vast
majority of overexpressed cullin-2-GFP is not assembled to endogenous
VHL (data not shown). Western blot analysis of nuclear and cytosolic
fractions obtained from VHL-negative 786-0 cells confirmed that the
subcellular distribution of endogenous cullin-2 was unaffected by
arrest of RNA polymerase II activity (Fig. 6B). However,
immunoprecipitation analysis revealed that the subcellular distribution
of the pool of cullin-2 that is bound to VHL-GFP, in 786-0 cells stably
expressing VHL-GFP, was sensitive to ongoing RNA polymerase II
transcription (Fig. 6C). Therefore, only cullin-2 that is
found assembled with VHL-GFP is sensitive to ongoing RNA polymerase II
for its localization, suggesting that VHL is able to confer
transcription-dependent nuclear export properties to cullin-2.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 6.
VHL confers
transcription-dependent nucleocytoplasmic trafficking
properties to cullin-2. A, subcellular localization of
a cullin-2-GFP fusion protein. HeLa cells were transiently transfected
with pCDNA3.1 vector expressing a cullin-2-GFP fusion protein, and
cells were observed 24 h after transfection either not treated
(a) or treated (c) with 25 µg/ml DRB for 2 h. Hoescht stain is shown in b and d.
B, effect of DRB treatment on the subcellular localization
of endogenous cullin-2 in VHL-negative 786-0 cells. VHL-negative 786-0 cells were either not treated ( ) or treated (+) for 2 h with 25 µg/ml DRB, trypsinized, washed in PBS, and treated with 50 µg/ml
digitonin for 5 min at 4 °C. The nuclei were collected by
centrifugation (300 × g) and separated from the
cytosolic fraction (Cytosolic; 17 µg of protein/lane).
Nuclei were washed in ice-cold transport buffer and treated with Triton
X-100 for 30 min at 4 °C (Nuclear; 100 µg/lane).
Total corresponds to unfractionated, Triton-soluble,
cellular lysate obtained from 786-0 cells (60 µg/lane). Blots were
incubated with an anti-cullin-2 antibody. C, effect of DRB
treatment on the subcellular localization of endogenous cullin-2 bound
to VHL-GFP in stably expressing 786-0 cells. VHL-GFP-expressing 786-0 cells were treated as described in B. Equal portions of the
total cellular extract (Total) Triton-soluble nuclear
fraction (Nuclear), and cytosolic fraction
(Cytosolic) were immunoprecipitated with M2 beads. Beads
were washed, boiled in 2× SDS loading buffer, and loaded on SDS-PAGE.
After transfer, the blots were incubated with the anti-cullin-2
antibody (top panel) or anti-Flag M2 antibody
(bottom panel). Different exposure times of the
autoradiograms are shown for the total, nuclear, and cytosolic
fractions. The band underneath VHL-GFP in the nuclear fraction is the
heavy chain of the M2 antibody.
|
|
Data presented in Figs. 5 and 6 suggested that VHL is able to export
from nuclei unassembled to cullin-2. If this were the case, it would be
predicted that VHL might encode information that directs its own
nuclear export and that of the reporter GFP both in living cells and
in vitro. To further investigate this possibility, a
C-terminal truncation mutant of VHL,
C157-GFP, which does not bind
to elongin BC and cullin-2, was tested for its ability to mediate
nuclear export of the reporter GFP in living cells and in
vitro (8, 12).
C157-GFP showed increased nuclear localization
at steady state compared with VHL-GFP and upon addition of DRB
accumulated more into the nucleus (Fig.
7A, a and
b). Removal of DRB caused
C157-GFP to return to its
original distribution (Fig. 7A, c). However, a
substantial portion of
C157-GFP remained in the nucleus, in a manner
reminiscent of VHL-GFP, when the washout experiments were performed at
4 °C or in the presence of metabolic poisons (Fig. 7A,
d and e). Like VHL-GFP,
C157-GFP was readily exported from nuclei in vitro at 20 °C in the standard
export conditions, but not in buffer only (Fig. 7B,
a-d). In contrast, no significant difference was observed
with PK-GFP-NLS, a fusion protein that is unable to export from nuclei
in vitro (Fig. 7B, e and
f). The GFP-GFP fusion protein was undetectable in nuclei regardless of the different incubation conditions (Fig. 7B,
g and h), or at 4 °C (data not shown)
demonstrating that this fusion protein is able to passively diffuse out
of the nucleus (see Fig. 1C). Nuclear export of
C157-GFP
was monitored in the biochemical assay (Fig. 7C). The fusion
protein exported only in the presence of HeLa extract and NTPs and
accumulated in the supernatant fraction, such as VHL-GFP, demonstrating
that the mutant protein was not degraded in the nucleus. Time lapse
imaging of
C157-GFP in vitro nuclear export indicated a
t1/2 of 5-7 min (Fig. 7, D and
E). These results demonstrate that the first 157 amino acids
of VHL are able to confer nuclear export activity to a GFP reporter
protein independently of its interaction with BC/Cul-2.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 7.
VHL encodes activity that mediates its own
nuclear export in living cells and in vitro.
A, effect of RNA polymerase II activity on C157-GFP
localization in living cells. HeLa cells were transiently transfected
with C157-GFP (a) and treated with DRB for 2 h at
37 °C (b). DRB was removed from the media and cells were
incubated at 37 °C (c), at 4 °C (d), or at
37 °C in the presence of 6 mM 6-deoxyglucose, 0.02%
sodium azide (e) for 2 h and in the presence of
cycloheximide (25 µg/ml). B, nuclear export of C157-GFP
in vitro. HeLa cells were transiently transfected with
VHL-GFP, and C157-GFP, PK-GFP-NLS, and GFP-GFP. Cells were
permeabilized with digitonin, washed for 15 min at 4 °C, and
incubated for 30 min at 20 °C in transport buffer
(Buffer) or in transport buffer containing HeLa cytosolic
extract, 2 mM ATP/GTP, and an ATP regeneration system
(Lysate, ATP/GTP). C, biochemical
analysis of C157-GFP nuclear export in vitro. HeLa cells
were transfected with C157-GFP. Nuclei were incubated at 20 °C
with transport buffer (buffer) or complete export reaction
mixture that consists of the HeLa cytosolic lysate and an ATP
regeneration system (L/E). Reaction time was either 0 or 30 min, as indicated. Nuclei were collected by centrifugation, and
separated from the cytosolic fraction. Equal aliquots of nuclei and
cytosolic fractions were separated on SDS-PAGE. Blots were incubated
with an anti-FLAG M2 antibody to detect VHL-GFP. D, time
lapse imaging of C157-GFP nuclear export in vitro. HeLa
cells expressing C157-GFP were permeabilized and incubated in
buffer, or in standard conditions (Lysate
ATP/GTP). Low magnification digital images were taken at the
indicated times during the export assay. E, quantitative
analysis of the nuclear export rate of C157-GFP. Average and
standard errors of three independent experiments are shown.
|
|
 |
DISCUSSION |
An in Vitro Assay to Reconstitute Nuclear Export of
VHL-GFP--
The VHL tumor suppressor gene product belongs to a group
of proteins that require transcription-dependent
nuclear/cytoplasmic shuttling to perform their respective role
(54-65). We have previously shown that nuclear export of VHL required
ongoing RNA Polymerase II activity but was insensitive to leptomycin B,
a drug that inhibits CRM-1-mediated nuclear export of proteins
containing a classical NES (33, 34). We, therefore, decided to make use
of an in vitro digitonin-permeabilized cell assay to
elucidate mechanisms involved in VHL-GFP nuclear export. Nuclear export
of VHL-GFP readily occurred when nuclei were incubated with transport
buffer supplemented with soluble cytosolic factors and NTPs. Several sets of experiments were performed to demonstrate that the in vitro assay reflected the physiological nuclear export pathway utilized by VHL-GFP. Nuclear export of VHL-GFP occurred in a time-, temperature-, and ATP hydrolysis-dependent manner and was
inhibited by WGA, a compound that interferes with signal-mediated
nuclear export. Furthermore, VHL-GFP appeared to utilize a very
efficient pathway since its nuclear export rate was measured to be
similar to that of proteins containing a classical NES (45, 47, 52). The cell line used for this study expressed VHL-GFP to very low, near
physiological levels (29), explaining why nuclear signal is so weak and
comparable to 786-0 autofluorescence. While it is sometimes difficult
to distinguish specific signal from autofluorescence in a system in
which VHL-GFP is expressed to physiological levels, this does argue
that VHL-GFP nuclear export is not a consequence of overexpression of
the fusion protein and most likely represents a physiological event. In
support of the in vitro data are those obtained with the
intact cells, which also demonstrated that VHL-GFP nuclear export is a
process that is energy-dependent. The information required
to stimulate nuclear export of the VBC/Cul-2 complex appears to be
encoded by VHL since a mutant VHL, which does not assemble with its
known binding partners, was able to confer nuclear export properties to
a reporter GFP. Put together, these observations suggest that VHL may
encode a domain that mediates nuclear export as efficiently as a
classical NES.
Factors Required for Efficient Nuclear Export of VHL--
The
in vitro assay enabled the biochemical reconstitution of the
nuclear export pathway utilized by VHL. Our results suggest that at
least four independent factors are required for efficient nuclear
export of VHL-GFP: an ATP hydrolysis step, the presence of GTP, the
synthesis of polyadenylated RNA, and the small GTPase Ran. Omission of
exogenous ATP, or addition of a non-hydrolyzable analog, in the export
reaction mixture totally inhibited the ability of VHL to export from
the nucleus even in cells that maintained active transcription and in
the presence of Ran. It is still unclear why ATP hydrolysis is
necessary and when exactly this occurs in the nuclear export pathway.
ATP hydrolysis has been shown to be required for nuclear export of
other exportable substrates, such as REV-1 and glucocorticoid receptor
(45, 66). Perhaps ATP hydrolysis precedes Ran-dependent
nuclear export by giving rise to a transport competent VHL-GFP, which
might include its assembly with complexes containing polyadenylated
mRNAs. In support of this model are the results obtained with
cordycepin, a drug that inhibits polyadenylation of RNA. Cordycepin
partially inhibited nuclear export of VHL-GFP, suggesting that the
presence of mature, transportable, polyadenylated mRNAs might be
important for optimal VHL-GFP nuclear export. It is unlikely that ATP
hydrolysis alone is sufficient to stimulate VHL-GFP nuclear egression,
even if some loss of nuclear signal was detectable when HeLa lysate, or Ran, was omitted from the reaction mixture. Our interpretation is that
enough residual Ran (about 5% in our hands) is retained in
permeabilized nuclei to assist in some nuclear export of VHL-GFP.
Proteins that contain leucine-rich NES utilize a
CRM-1/Ran-dependent pathway to export from nuclei (67, 68).
Although VHL does not appear to require CRM-1, partial biochemical
fractionation of HeLa cytosolic extract and in vitro
reconstitution has revealed that it does export from nuclei through a
Ran-dependent pathway. In an effort to identify other
molecules that might be involved in nuclear export of VHL-GFP,
permeabilized cells were preincubated with ATP, a condition believed to
deplete nuclei of transport factors. Using this approach, Kehlenbach
and collaborators (52) elegantly showed that Ran-dependent
nuclear export of NFAT, a protein that harbors a classical NES,
necessitated an additional factor, CRM1, but only when nuclei were
preincubated in the presence of ATP. Such molecules do not appear to be
required for nuclear export of VHL-GFP, which suggest that Ran is the
only rate-limiting soluble cytosolic factor lost upon permeabilization.
Despite these observations, the requirement of other factors for
VHL-GFP nuclear export cannot be simply excluded. Perhaps other
molecules, such as
-transporters, are present in sufficient amounts
to assist in Ran-dependent nuclear export of VHL-GFP and
are not depleted by a prolong incubation with ATP. The identification
of these putative factors involved in nuclear export of VHL-GFP will be important as they may play a role in the ability of VHL to function as
a tumor suppressor. Regardless of the mechanisms involved in VHL
nuclear export, this occurs without Ran-mediated GTP hydrolysis. We
found that GMP-PNP could replace GTP and that the GTP
hydrolysis-defective RanG19V stimulated VHL-GFP export to levels
similar to those of wild-type Ran, consistent with a model in which
RanGTP, but not Ran-mediated GTP hydrolysis, is required for nuclear
export of proteins (53).
VHL Encodes Sequences That Mediate Its Own Nuclear
Export--
Immunoprecipitation and column chromatography analyses
have revealed at least two independent populations of nuclear VHL-GFP distinguished by the fact that VHL is either assembled or unassembled with cullin-2. The same two populations were also detected in the
supernatant after completion of the nuclear export reaction, suggesting
that VHL-GFP is able to stimulate nuclear export of the reporter GFP
without being assembled to cullin-2. This is highlighted by data
obtained with
C157-GFP, a mutant VHL that is unable to assemble with
elongin BC/cullin-2.
C157-GFP conferred nuclear export properties to
an inert GFP reporter as efficiently as other proteins that contain a
classical NES. The fact that another fusion protein (PK) was unable to
stimulate nuclear export of GFP, as predicted (49), also argues that
VHL encodes sequences that act as a nuclear export domain. Since VHL is
able to stimulate its own nuclear export, it is tempting to speculate
that it might also have a role in mediating cullin-2 nuclear export.
Data presented here support the claim that VHL is, at least in part,
able to confer transcription-dependent nuclear export
properties to cullin-2. This is accentuated by the observation that,
contrarily to VHL-GFP, cullin-2-GFP subcellular localization was
unaffected by treatment with DRB. The localization of endogenous
cullin-2 in a VHL-negative background was also insensitive to DRB. In
contrast, the fraction of cullin-2 that is assembled to VHL-GFP is
sensitive to DRB strongly suggesting that the
transcription-dependent nuclear export properties of the
VHL-GFP/cullin-2 complex is conferred by VHL sequences. Obviously, it
is difficult to rule out that VHL, elongin BC, and cullin-2 are all
able to engage in nuclear export independently and then reassemble in
the supernatant. Some of the experiments were performed in the presence
of a peptide comprising of the elongin C binding box, which should
normally prevent reassembly of cullin-2/elongin C with free VHL.
However, this control does not totally exclude the possibility that
cullin-2 might engage in nuclear export independently of its assembly
with VHL, perhaps by using a different pathway. If this were the case,
cullin-2 would disassemble with VHL in the nucleus, engage in nuclear
export, and then reassemble in the cytoplasm. Although we favor a model by which VHL, elongin BC and cullin-2 export out of nuclei as a
complex, it will be difficult to resolve this question until we achieve
a better understanding on how and when VHL binds to its partners.
Regardless of the way cullin-2 is exported out of the nucleus, we have
presented data suggesting that VHL encodes information that directs its
own nuclear export and that of a reporter GFP in living cells and
in vitro. Nuclear export of VHL-GFP occurs through a
signal-mediated pathway that requires Ran, ATP hydrolysis, and ongoing
RNA polymerase II activity. Since VHL does not appear to contain
leucine-rich sequences or a M9-like domain (61, 69, 70), fine mapping
of these sequences will be required to identify the smallest region
responsible for rapid nuclear export of VHL. Several cancer-causing
substitutions found in sporadic RCC do not affect the ability of VHL to
assemble with elongin BC/cullin-2 and appear to inactivate a yet
undescribed VHL tumor suppression function (71). Some of these
inactivating substitutions may prevent efficient nuclear export of VHL.
It will be important to pursue studies detailing the relationship
between the ability of VHL to mediate its own nuclear export, perhaps
that of cullin-2, and its tumor suppressor function. The in
vitro assay presented here will provide a valuable tool to answer
these questions as well as dissect the molecular mechanisms involved in
nucleocytoplasmic shuttling of VHL and its associated proteins.
 |
ACKNOWLEDGEMENTS |
We sincerely thank Marie-Christine Fournier
and Angelique Arpin for excellent technical contributions to this work.
We also thank Robert Haché, Ruth Slack, and Mary Dasso for
critical reviews and comments. We thank Petr Kalab for the purified Ran
and RanG19V.
 |
FOOTNOTES |
*
This work was supported in part by an operating grant from
the Medical Research Council of Canada (to S. L.)The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Scholar of the Medical Research Council. To whom correspondence
should be addressed: Dept. of Cellular and Molecular Medicine, Faculty
of Medicine, University of Ottawa, 451 Smyth Rd., Ottawa, Ontario K1H
8M5, Canada. Tel.: 613-562-5800 (ext. 8385); Fax: 613-562-5636; E-mail:
slee@uottawa.ca.
 |
ABBREVIATIONS |
The abbreviations used are:
VHL, von
Hippel-Lindau;
GFP, green fluorescent protein;
RCC, renal clear cell
carcinoma;
AMP-PNP, adenosine 5'-(
,
-imino)triphosphate;
GMP-PNP, 5'-guanylimidodiphosphate;
WGA, wheat germ agglutinin;
NES, nuclear
export signal;
PAGE, polyacrylamide gel electrophoresis;
PBS, phosphate-buffered saline;
GTP
S, guanosine
5'-3-O-(thio)triphosphate;
PK, pyruvate kinase.
 |
REFERENCES |
| 1.
|
Gnarra, J. R.,
Duan, D. R.,
Weng, Y.,
Humphrey, J. S.,
Chen, D. Y.,
Lee, S.,
Pause, A.,
Dudley, C. F.,
Latif, F.,
Kuzmin, I.,
Schmidt, L.,
Duh, F. M.,
Stackhouse, T.,
Chen, F.,
Kishida, T.,
Wei, M. H.,
Lerman, M. I.,
Zbar, B.,
Klausner, R. D.,
and Linehan, W. M.
(1996)
Biochim. Biophys. Acta
1242,
201-210[Medline]
[Order article via Infotrieve]
|
| 2.
|
Latif, F.,
Tory, K.,
Gnarra, J.,
Yao, M.,
Duh, F.-M.,
Orcutt, M. L.,
Stackhouse, T.,
Kuzmin, I.,
Modi, W.,
Geil, L.,
Schmidt, L.,
Zhou, F.,
Li, H.,
Wei, M.-H.,
Chen, F.,
Glenn, G.,
Choyke, P.,
Walther, M. M.,
Weng, Y.,
Duan, D.-S. R.,
Dean, M.,
Glavac, D.,
Richards, F. M.,
Crossey, P. A.,
Ferguson-Smith, M. A.,
Le Paslier, D.,
Chumakov, I.,
Cohen, D.,
Chinault, A. C. R.,
Maher, E. R.,
Linehan, W. M.,
Zbar, B.,
and Lerman, M.I.
(1993)
Science
260,
1317-1320[Abstract/Free Full Text]
|
| 3.
|
Linehan, W. M.,
Lerman, M. I.,
and Zbar, B.
(1995)
J. Am. Med. Assoc.
273,
564-570[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Foster, K.,
Prowse, A.,
van den Berg, A.,
Fleming, S.,
Hulsbeek, M. M. F.,
Crossey, P. A.,
Richards, F. M.,
Cairns, P.,
Affara, N. A.,
Ferguson-Smith, M. A.,
Buys, C. H.,
and Maher, E. R.
(1994)
Hum. Mol. Genet.
3,
2169-2173[Abstract/Free Full Text]
|
| 5.
|
Gnarra, J. R.,
Tory, K.,
Weng, Y.,
Schmidt, L.,
Wei, M. H.,
Li, H.,
Latif, F.,
Liu, S.,
Chen, F.,
Duh, F. M.,
Lubensky, I.,
Duan, D. R.,
Florence, C.,
Pozzatti, R.,
Walther, M. M.,
Bander, N. H.,
Grossman, H. B.,
Brauch, H.,
Pomer, S.,
Brooks, J. D.,
Isaacs, W. B.,
Lerman, M. J.,
Zbar, B.,
and Linehan, W. M.
(1994)
Nat. Genet.
7,
85-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Kaelin, W. G.,
and Maher, E. R.
(1998)
Trends Genet.
14,
423-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kinzler, K. W.,
and Vogelstein, B.
(1997)
Nature
386,
761[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Pause, A.,
Lee, S.,
Lonergan, K. M.,
and Klausner, R. D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
993-998[Abstract/Free Full Text]
|
| 9.
|
Iliopoulos, O.,
Kibel, A.,
Gray, S.,
and Kaelin, W. G.
(1995)
Nat. Med.
1,
822-826[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Gnarra, J. R.,
Zhou, S.,
Merrill, M. J.,
Wagner, J. R.,
Krumm, A.,
Papavassiliou, E.,
Oldfield, E. H.,
Klausner, R. D.,
and Linehan, W. M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10589-10594[Abstract/Free Full Text]
|
| 11.
|
Iliopoulos, O.,
Levy, A. P.,
Jiang, C.,
Kaelin, W. G., Jr.,
and Goldberg, M. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10595-10599[Abstract/Free Full Text]
|
| 12.
|
Lonergan, K. M.,
Iliopoulos, O.,
Ohh, M.,
Kamura, T.,
Conaway, R. C.,
Conaway, J. W.,
and Kaelin, W. G.
(1998)
Mol. Cell. Biol.
18,
732-741[Abstract/Free Full Text]
|
| 13.
|
Seimeister, G.,
Weidel, K.,
Mohrs, K.,
Barleon, B.,
Martiny-Baron, G.,
and Marne, D.
(1996)
Cancer Res.
56,
2299-2301[Abstract/Free Full Text]
|
| 14.
|
Ohh, M.,
Yauch, R. L.,
Lonergan, K. M.,
Whaley, J. M.,
Stemmer-Rachamimov, O. D.,
Louis, A. N.,
Gavin, B. J.,
Kley, N.,
Kaelin, W. G.,
and Iliopoulos, O.
(1998)
Mol. Cell
1,
959-968[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Lieubeau-Teillet, B.,
Rak, J.,
Jothy, S.,
Iliopoulos, O.,
Kaelin, W. G.,
and Kerbel, R. S.
(1998)
Cancer Res.
58,
4957-4962[Abstract/Free Full Text]
|
| 16.
|
Blankenship, C,
Naglich, J. G.,
Whaley, J. M.,
Seizinger, B.,
and Kley, N.
(1999)
Oncogene
18,
1529-153[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Iliopoulos, O.,
Ohh, M.,
and Kaelin, W. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11661-11666[Abstract/Free Full Text]
|
| 18.
|
Schoenfeld, A.,
Davidowitz, E. J.,
and Burk, R. D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8817-8822[Abstract/Free Full Text]
|
| 19.
|
Duan, D. R.,
Pause, A.,
Burgess, W. H.,
Aso, T.,
Chen, D. Y. T.,
Garrett, K. P.,
Conaway, R. C.,
Conaway, J. W.,
Linehan, W. M.,
and Klausner, R. D.
(1995)
Science
269,
1402-1406[Abstract/Free Full Text]
|
| 20.
|
Kibel, A.,
Iliopoulos, O.,
DeCaprio, J. A.,
and Kaelin, W. G.
(1995)
Science
269,
1444-1446[Abstract/Free Full Text]
|
| 21.
|
Pause, A.,
Lee, S.,
Worrell, R. A.,
Chen, D. Y. T.,
Burgess, W. H.,
Linehan, W. M.,
and Klausner, R. D.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2156-2161[Abstract/Free Full Text]
|
| 22.
|
Gorospe, M.,
Egan, J. M.,
Zbar, B.,
Lerman, M.,
Geil, L.,
Kuzmin, I.,
and Holbrook, N. J.
(1999)
Mol. Cell. Biol.
19,
1289-1300[Abstract/Free Full Text]
|
| 23.
|
Kamura, T.,
Koepp, D. M.,
Conrad, M. N.,
Skowyra, D.,
Moreland, R. J.,
Iliopoulos, O.,
Lane, W. S.,
Kaelin, W. G.,
Elledge, S. J.,
Conaway, R. C.,
Harper, J. W.,
and Conaway, J. W.
(1999)
Science
284,
657-661[Abstract/Free Full Text]
|
| 24.
|
Lisztwan, J.,
Imbert, G.,
Wirbelauer, C.,
Gstaiger, M.,
and Krek, W.
(1999)
Genes Dev.
13,
1822-1833[Abstract/Free Full Text]
|
| 25.
|
Maxwell, P. H.,
Wiesener, M. S.,
Chang, G. W.,
Clifford, S. C.,
Vaux, E. C.,
Cockman, M. E.,
Wykoff, C. C.,
Pugh, C. W.,
Maher, E. R.,
and Racliff, P. J.
(1999)
Nature
399,
271-275[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Knebelmann, B.,
Ananth, B.,
Cohen, H. T.,
and Sukhatme, V. P.
(1998)
Cancer Res.
58,
226-231[Abstract/Free Full Text]
|
| 27.
|
Corless, C. L.,
Kibel, A.,
Iliopoulos, O.,
and Kaelin, W. G.
(1997)
Hum. Pathol.
28,
459-464[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Lee, S.,
Chen, D. Y. T.,
Humphrey, J. S.,
Gnarra, J. R.,
Linehan, W. M.,
and Klausner, R. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1770-1775[Abstract/Free Full Text]
|
|